JP2023519890A5 - - Google Patents

Info

Publication number
JP2023519890A5
JP2023519890A5 JP2022558423A JP2022558423A JP2023519890A5 JP 2023519890 A5 JP2023519890 A5 JP 2023519890A5 JP 2022558423 A JP2022558423 A JP 2022558423A JP 2022558423 A JP2022558423 A JP 2022558423A JP 2023519890 A5 JP2023519890 A5 JP 2023519890A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
inhibitors
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519890A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024482 external-priority patent/WO2021195562A1/en
Publication of JP2023519890A publication Critical patent/JP2023519890A/ja
Publication of JP2023519890A5 publication Critical patent/JP2023519890A5/ja
Pending legal-status Critical Current

Links

JP2022558423A 2020-03-27 2021-03-26 免疫状態の処置のためのｍｋ２経路阻害剤の経口組成物 Pending JP2023519890A (ja)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US202063000746P 2020-03-27 2020-03-27
US63/000,746 2020-03-27
US202063015241P 2020-04-24 2020-04-24
US63/015,241 2020-04-24
US202063018954P 2020-05-01 2020-05-01
US63/018,954 2020-05-01
US202063022301P 2020-05-08 2020-05-08
US202063022298P 2020-05-08 2020-05-08
US63/022,301 2020-05-08
US63/022,298 2020-05-08
US202063024160P 2020-05-13 2020-05-13
US63/024,160 2020-05-13
US202063053903P 2020-07-20 2020-07-20
US63/053,903 2020-07-20
US202063076689P 2020-09-10 2020-09-10
US63/076,689 2020-09-10
US202063126173P 2020-12-16 2020-12-16
US63/126,173 2020-12-16
US202063128523P 2020-12-21 2020-12-21
US63/128,523 2020-12-21
US202163136080P 2021-01-11 2021-01-11
US63/136,080 2021-01-11
US202163136967P 2021-01-13 2021-01-13
US63/136,967 2021-01-13
US202163138672P 2021-01-18 2021-01-18
US63/138,672 2021-01-18
US202163140116P 2021-01-21 2021-01-21
US63/140,116 2021-01-21
US202163149230P 2021-02-13 2021-02-13
US63/149,230 2021-02-13
PCT/US2021/024482 WO2021195562A1 (en) 2020-03-27 2021-03-26 Oral compositions of mk2 pathway inhibitor for treatment of immune conditions

Publications (2)

Publication Number Publication Date
JP2023519890A JP2023519890A (ja) 2023-05-15
JP2023519890A5 true JP2023519890A5 (https=) 2024-04-04

Family

ID=77890611

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022558423A Pending JP2023519890A (ja) 2020-03-27 2021-03-26 免疫状態の処置のためのｍｋ２経路阻害剤の経口組成物
JP2022558424A Pending JP2023519891A (ja) 2020-03-27 2021-03-26 置換ピリジノン－ピリジニル化合物のプロセス、組成物、および結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022558424A Pending JP2023519891A (ja) 2020-03-27 2021-03-26 置換ピリジノン－ピリジニル化合物のプロセス、組成物、および結晶形態

Country Status (12)

Country Link
US (4) US20230149400A1 (https=)
EP (2) EP4132524A4 (https=)
JP (2) JP2023519890A (https=)
KR (2) KR20220161396A (https=)
CN (4) CN119235863A (https=)
AU (2) AU2021244255A1 (https=)
BR (1) BR112022019349A2 (https=)
CA (2) CA3172088A1 (https=)
IL (1) IL296054A (https=)
MX (2) MX2022011748A (https=)
PH (2) PH12022552321A1 (https=)
WO (3) WO2021195507A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220161396A (ko) 2020-03-27 2022-12-06 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
EP4247380A4 (en) * 2020-11-23 2025-03-05 Aclaris Therapeutics, Inc. PROCESSES FOR THE SYNTHESIS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS
BR112023019861A2 (pt) 2021-03-31 2023-11-07 Xinthera Inc Inibidores de mk2 e usos dos mesmos
EP4367099A4 (en) 2021-07-09 2025-06-04 Xinthera, Inc. Pyridinone mk2 inhibitors and uses thereof
WO2023125708A1 (zh) * 2021-12-29 2023-07-06 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116396274B (zh) * 2022-01-06 2025-11-11 深圳信立泰药业股份有限公司 一种取代的联吡啶酮类化合物及其制备方法与应用
CN116444493A (zh) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 含双并环类衍生物、其制备方法和应用
WO2023150709A2 (en) * 2022-02-04 2023-08-10 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
EP4593823A1 (en) * 2022-09-30 2025-08-06 Abbvie Inc. Methods of treating hidradenitis suppurativa
TW202428271A (zh) * 2022-11-16 2024-07-16 大陸商上海美悦生物科技發展有限公司 吡啶氮氧化物類衍生物及其藥物組合物、製備方法和用途
KR20240078816A (ko) 2022-11-28 2024-06-04 주식회사 엘지에너지솔루션 에이징 시스템
EP4650347A1 (en) 2023-01-13 2025-11-19 Shanghai Meiyue Biotech Development Co., Ltd. Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof
JP2026504073A (ja) * 2023-01-13 2026-02-03 プールベグ ファーマ（ユーケー） リミテッド がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法
WO2025093869A1 (en) * 2023-11-01 2025-05-08 Poolbeg Pharma (UK) Limited P38 map kinase inhibitor for use in the treatment of inflammation

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
JP2003500403A (ja) 1999-05-21 2003-01-07 サイオス，インコーポレーテッド ｐ３８キナーゼのインヒビターとしてのインドール型誘導体
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
EP1341782A2 (en) 2000-11-20 2003-09-10 Scios Inc. Inhibitors of p38 kinase
US7314752B2 (en) 2001-07-19 2008-01-01 Common Sense, Ltd. Secretion-monitoring article
ATE448784T1 (de) 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
JP2005255675A (ja) 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd 医薬組成物
CN1976915A (zh) 2004-02-11 2007-06-06 史密丝克莱恩比彻姆公司 Hiv整合酶抑制剂
US7936407B2 (en) 2005-02-24 2011-05-03 Samsung Electronics Co., Ltd. Array substrate, method of manufacturing the same, display panel having the same, and liquid crystal display apparatus having the same
BRPI0607913A2 (pt) 2005-04-08 2010-03-23 Eisai R&D Man Co Ltd agente terapÊutico para discinesia
TW200740755A (en) 2005-07-13 2007-11-01 Bayer Cropscience Sa Dihalogenation of N,O-disubstituted hydroxypyridones and their uses
WO2007081901A2 (en) 2006-01-05 2007-07-19 The Scripps Research Institute Pyrimidinone derivatives as protein kinase inhibitors
UY30378A1 (es) 2006-06-02 2008-01-02 Janssen Pharmaceutica Nv Nuevos derivados de piridinona n-aril y n-heteroaril sustituidos para usar en enfermedades mediadas por mch-1
ES2426780T3 (es) 2006-07-14 2013-10-25 Amgen Inc. Compuestos de piridona sustituidos con alquino y métodos de uso
KR20090085117A (ko) 2006-11-24 2009-08-06 다케다 야쿠힌 고교 가부시키가이샤 헤테로모노시클릭 화합물 및 이의 용도
BRPI0720049A2 (pt) 2006-12-07 2014-01-07 Novartis Ag Derivados de piridina utilizados como inibidores de xiap
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
WO2008153942A1 (en) 2007-06-06 2008-12-18 Xcovery, Inc. Kinase inhibitor compounds
EA016595B1 (ru) 2007-07-17 2012-06-29 Бристол-Маерс Сквибб Компани Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
US9187426B2 (en) 2008-06-27 2015-11-17 Novartis Ag Organic compounds
EP2334673A1 (en) * 2008-08-29 2011-06-22 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
AU2010302420B2 (en) * 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
SI2648516T1 (sl) 2010-12-06 2019-01-31 Aclaris Therapeutics, Inc. Substituirane spojine piridinon-piridinila
US9056110B2 (en) 2011-12-06 2015-06-16 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
HUE054178T2 (hu) * 2013-06-07 2021-08-30 Aclaris Therapeutics Inc Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek
WO2015161908A1 (en) * 2014-03-11 2015-10-29 Ludwig-Maximilians-Universität München Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections
WO2017048702A1 (en) * 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3720436A4 (en) 2017-12-06 2021-06-02 Lin Bioscience, Pty Ltd. TUBULIN INHIBITORS
JP2022542434A (ja) 2019-07-31 2022-10-03 アクラリス セラピューティクス，インコーポレイテッド 重水素化ｍｋ２経路阻害剤およびその使用方法
US20230087078A1 (en) 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
KR20220161396A (ko) 2020-03-27 2022-12-06 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형

Similar Documents

Publication Publication Date Title
JP2023519890A5 (https=)
AU2019358948B2 (en) STING Agonistic Compound
CN107864625B (zh) 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
US9012444B2 (en) Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
HK1250645A1 (zh) 取代的2，3-二氢咪唑并[1，2-c]喹唑啉类化合物的用途
EP1663244A2 (en) Pteridine derivatives for the treatment of septic shock and tnf-alpha-related diseases.
CA2453687A1 (en) Therapeutic composition containing at least diflomotecan and capecitabin e
JP6855488B2 (ja) 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット
JPS6360936A (ja) 複合薬剤
EP2513089B1 (en) 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
US8957103B2 (en) Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
US20020111328A1 (en) Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
JP2024515215A5 (https=)
IL307990A (en) Antimicrobial and anticancer agents
CN110025617B (zh) 双去甲基汉防己甲素双甲酸乙酯与酪氨酸激酶抑制剂的药物组合物
CN114173785A (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
CA2603809C (en) Radiotherapy enhancer
CN111840289A (zh) 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐
AU2007316217A1 (en) A method of administering an antitumor compound
KR102501514B1 (ko) 2'-아미노-6-(2-아미노-6-(1-이소프로필피페리딘-4-일)-5-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 3염산염 및 이를 포함하는 약제학적 조성물
CZ299465B6 (cs) Kombinace s obsahem pyridoindolonového derivátu aprotinádorového cinidla
CN100496498C (zh) 含有依那普利或贝那普利和索他洛尔的药物组合物
EP3397632A1 (en) 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
Li Chemotherapy for Gynecologic Cancer Quan Li and Jack L. Watkins Chemotherapeutic Agents in Gynecologic Oncology
HK40053745A (en) Sting-agonist compound